Home > Signaling Pathways>Metabolism>CETP>Anacetrapib (MK-0859)
Anacetrapib (MK-0859)

This product is for research use only, not for human use. We do not sell to patients.

Anacetrapib (MK-0859)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
100mg$850Check With Us
250mg$1400Check With Us
500mg$2100Check With Us

Cat #: V0911 CAS #: 875446-37-0 Purity ≥ 98%

Description: Anacetrapib (formerly also known as MK0859; MK-0859), a poly-fluorinated lipophilic compound, is a selective and reversible inhibitor of CETP (Cholesteryl ester transfer protein) and mutant CETP(C13S) with the potential to treat cardiovascular disease.

References: Niesor EJ, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010, 51(12), 3443-3454.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)637.51
Molecular FormulaC30H25F10NO3
CAS No.875446-37-0
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 127 mg/mL (199.2 mM)r
Water: <1 mg/mLr
Ethanol: 127 mg/mL (199.2 mM)
Solubility In Vivo30% PEG400+0.5% Tween80+5% propylene glycol: 10 mg/mL
SMILES CodeO=C1O[C@H](C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)[C@H](C)N1CC3=CC(C(F)(F)F)=CC=C3C4=CC(C(C)C)=C(F)C=C4OC
SynonymsMK 0859; Anacetrapib; MK0859; MK-0859;
ProtocolIn VitroAnacetrapib dose-dependently and significantly decreases the transfer of CE from HDL3 to HDL2 (P<0.001 for concentrations equal to and higher than 0.1 µM). Excess Anacetrapib (25 µM) decreases the amount of [14C]Torcetrapib (0.25 µM) binds to immobilized rhCETP by 82% and 60%, respectively. Anacetrapib decreases pre-β-HDL formation by more than 46% (P<0.001) at all concentrations tested (0.1, 1, 3, and 10 µM).
In VivoHamsters are given Anacetrapib for 7 days before injection of [3H]cholesterol-labeled macrophages (day 0). Treatment with Anacetrapib leads to significant increases in HDL-C levels at day 0. At day 3, [3H]cholesterol radioactivity in the HDL fraction is significantly increased from control values for Anacetrapib.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM1.5686 mL7.8430 mL15.6860 mL31.3721 mL
5mM0.3137 mL1.5686 mL3.1372 mL6.2744 mL
10mM0.1569 mL0.7843 mL1.5686 mL3.1372 mL
20mM0.0784 mL0.3922 mL0.7843 mL1.5686 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.